The Hims & Hers SPAC deck serves as a masterclass in presenting a high-growth consumer brand as a vertically integrated healthcare infrastructure play. By the time of this filing in 2020, the company had achieved a 128% revenue CAGR and expanded its gross margins from 29% to 71% in just two years. The presentation focuses heavily on the 'flywheel' effect of its multi-condition platform, showing how initial successes in hair loss and erectile dysfunction provided the data and capital to enter massive markets like primary care ($280bn) and dermatology ($44bn). The transaction summary details a…
Key takeaways
- The company reported a 128% revenue CAGR, growing from $27 million in 2018 to an estimated $138 million in 2020 (Slide 31).
- Gross margins expanded significantly from 29% in 2018 to 71% in 2020, representing a 254% CAGR in gross profit (Slide 31).
- The platform achieved over 2 million telemedicine consultations since launch, with 10 million cumulative patient touchpoints by Q2 2020 (Slide 16).
- Hims & Hers identifies a $280 billion market opportunity in primary care and a $44 billion opportunity in dermatology as key expansion pillars (Slide 21).
- The leadership team features executives with backgrounds from Walgreens, Bonobos, Google, Netflix, and Stanford Medicine (Slide 6).
- The transaction summary establishes a pro forma enterprise value of $1.592 billion, trading at 8.9x 2021E revenue (Slide 36).
- The business model is built on a fully verticalized stack including a distributed provider network, cloud pharmacy, and digital native EMR (Slide 11).
- Enterprise expansion is a core strategy, offering a turnkey telehealth option for employers with 24/7 in-house coverage (Slide 26).
The SPAC Transition: Scaling Healthcare Infrastructure
The Hims & Hers SPAC deck represents a pivotal moment for the company as it transitioned from a venture-backed startup to a public entity. Unlike early-stage decks that focus on problem-solution fit, this presentation is built on the foundation of proven unit economics and aggressive market expansion. With a $1.6 billion valuation on the line, the narrative shifts from 'what we might do' to 'how fast we are winning.' The deck uses 43 slides to detail a vertically integrated health platform that has successfully de-stigmatized sensitive medical conditions through a consumer-first lens.
Slide 1: Brand Identity and Visual Language
The cover slide sets the tone for the entire presentation. It features high-quality lifestyle photography of a diverse couple, emphasizing the 'Hers' side of the brand just as much as the 'Hims' side. The typography is clean and serif-based, distancing the company from the clinical, sterile aesthetic of traditional healthcare providers. This visual choice reinforces the company's position as a consumer brand that happens to provide medical services.
Slide 6: The Leadership Bench
Slide 6 presents a 'visionary founder and veteran leadership' team. The slide is structured to show a balance between high-growth consumer tech and institutional healthcare. CEO Andrew Dudum is linked to Atomic, while CFO Spencer Lee brings experience from Minted. Crucially, the clinical side is anchored by Patrick Carroll (Chief Medical Officer, formerly of Walgreens) and Leah Millheiser (SVP Medical Affairs, Stanford Medicine). By listing logos like Google, Netflix, and Teladoc, the company signals to investors that it has the operational maturity to handle a $1.6 billion public listing.
Slide 11: The Vertical Integration Stack
This slide defines the company's competitive moat. Hims & Hers describes itself as the 'first digitally native, fully verticalized multi-condition health platform.' The stack includes six key components: Consumer Brand , Distributed Provider Network , Clinically Focused EMR , Digital Native Telemedicine Platform , Digital Prescriptions , and Cloud Pharmacy . By owning the entire journey from the first ad click to the delivery of the medication, the company argues it can maintain higher margins and a better patient experience than fragmented competitors.
Slide 16: Unprecedented Patient Growth
Traction is visualized through a steep upward curve. As of Q2 2020, the company reported 2 million+ H&H telemedicine consultations since launch. The slide also notes 10 million+ cumulative patient touchpoints , which includes follow-up messages, renewal visits, and shipments. The growth from 431k consultations in 2018 to 2.0 million by mid-2020 provides the quantitative evidence needed to justify the 'new paradigm of healthcare' claim made in the header.
Slide 21: Market Expansion and Fundamentals
This is a strategic roadmap slide. It categorizes conditions into 'Existing' (Hair Loss, ED), 'Recently Launched' (Anxiety & Depression, Dermatology, Primary Care), and 'Future Opportunities' (Sleep, Fertility, Diabetes, Cholesterol). The spend figures are massive, highlighted by a $280bn spend in Primary Care and $70bn in Diabetes . The table uses checkmarks to show that these new markets share the same 'key underlying fundamentals' as their initial successes: they are chronic, use generic medications, have a specialty focus, and are telemedicine-enabled. This slide effectively argues that the Hims & Hers model is infinitely repeatable across the healthcare landscape.
Slide 26: Enterprise and B2B Strategy
Slide 26 introduces 'Hims & Hers for enterprise,' a turnkey telehealth option for cost-conscious employers. The slide lists key benefits such as 24/7 in-house coverage and a 50-state prescription delivery network . By moving into the B2B space, the company demonstrates a diversified revenue stream beyond direct-to-consumer (DTC) marketing, which is often a concern for investors worried about rising customer acquisition costs (CAC).
Slide 31: Revenue Growth and Margin Expansion
This is arguably the most important slide for the valuation. It shows Annual Revenue growing at a 128% CAGR , reaching an estimated $138 million in 2020 . More impressively, it shows Gross Margin Expansion from 29% in 2018 to 71% in 2020 . A 71% gross margin is typical of software companies, not traditional healthcare providers. This margin expansion, growing at a 254% CAGR, is the primary driver behind the $1.6 billion valuation, as it proves the scalability of the verticalized model.
Slide 36: Transaction Summary
The financial mechanics of the SPAC deal are laid out here. The Pro Forma Enterprise Value is $1.592 billion , which represents 8.9x 2021E Revenue and 12.2x 2021E Gross Profit. The 'Sources & Uses' table shows $205 million from OAC Cash Held in Trust and $75 million from PIPE Investment Proceeds . Existing shareholders maintain approximately 84% ownership, signaling strong internal confidence in the post-merger performance.
Slide 41: The Appendix
The deck concludes with an appendix transition slide, featuring a close-up of skin care application. While the specific appendix data isn't in the provided selection, the 43-slide total suggests deep dives into cohort data, regulatory compliance, and detailed financial projections that institutional investors require during a SPAC process.
What Hims & Hers Does Well
The deck excels at re-framing a pharmacy business as a technology platform. By focusing on the 'fully verticalized' nature of their stack (Slide 11), they move the conversation away from 'selling pills' to 'owning the patient relationship.' The use of a 71% gross margin figure (Slide 31) is the ultimate proof of this tech-like efficiency. Furthermore, the expansion roadmap (Slide 21) is logically sound; they aren't just picking random markets, they are picking markets that fit their specific operational strengths (generic meds, chronic care, stigma).
What is Missing from the Deck
While the growth metrics are stellar, the deck is relatively quiet on Customer Acquisition Cost (CAC) and Long-Term Value (LTV) ratios. For a company that grew so heavily through social media advertising, investors usually want to see the 'payback period' for their marketing spend. Additionally, while Slide 11 mentions a 'Distributed Provider Network,' there is little detail on how they manage physician quality or the legal complexities of 50-state compliance, which are significant operational risks in telemedicine.
Founder Takeaways: The SPAC Standard
Founders should study Slide 31 for how to present financial growth. By showing both revenue and gross profit side-by-side, Hims & Hers proves that they aren't just buying growth—they are becoming more efficient as they scale. Another key takeaway is the 'Transaction Summary' (Slide 36). It is transparent, showing exactly where the money is coming from and how the ownership will look post-close. For any founder looking to go public or raise a late-stage round, this deck provides a blueprint for balancing high-level brand vision with hard-nosed financial reality.
Frequently asked questions
- What was the valuation of Hims & Hers at the time of this deck?
- According to Slide 36, the implied pro forma enterprise value was $1.592 billion. This was based on a $10.00 share price and approximately 192.6 million pro forma shares outstanding. The equity value was calculated at $1.927 billion, adjusted for $334 million in cash on the balance sheet and zero debt.
- How did Hims & Hers demonstrate its growth trajectory?
- The company used Slide 31 to show a massive jump in annual revenue from $27 million in 2018 to $83 million in 2019, reaching an estimated $138 million for 2020. This represents a 128% CAGR. Simultaneously, they highlighted gross profit growing from $8 million to $98 million in the same period.
- What markets does Hims & Hers plan to enter next?
- Slide 21 outlines 'Future Opportunities' in Sleep ($15bn spend), Fertility ($15bn), Diabetes ($70bn), and Cholesterol ($21bn). The deck argues that these markets are logical expansions because they are chronic conditions, involve generic medications, and are telemedicine-enabled, fitting the existing Hims & Hers infrastructure.
- Who are the key members of the leadership team?
- Slide 6 lists CEO Andrew Dudum (Atomic), CFO Spencer Lee (Minted), and CMO Patrick Carroll (Walgreens). Other veteran leaders include Melissa Baird (COO, Bonobos), Soleil Boughton (CLO, Google), and Julian Cohen (SVP Behavioral Health, Teladoc), emphasizing a mix of consumer retail and clinical healthcare expertise.
- What is the 'Hims & Hers for Enterprise' offering?
- Slide 26 describes an 'inexpensive turnkey telehealth option' for employers. It features 24/7 in-house coverage, a 50-state prescription delivery network, and access to ~500 affordable medications. The goal is to provide value-based pricing for organizations covering sexual health, mental health, and primary care for employees.
